Aarkstore - TGF-Beta-2 Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - TGF-Beta-2 Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0f0d-ZjViM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - TGF-Beta-2 Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,TGF-Beta-2 Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under TGF-Beta-2 Inhibitors. – PowerPoint PPT presentation

Number of Views:25

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - TGF-Beta-2 Inhibitors -Pipeline Insights, 2014


1
TGF-Beta-2 Inhibitors -Pipeline Insights,
2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/76036/tgf-beta-2-inhibitors-pipeline-insights-20
    14

2
Summary
  • DelveInsights,TGF-Beta-2 Inhibitors-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    mechanism of action (MOA). A key objective of the
    report is to establish the understanding for all
    the pipeline drugs that fall under TGF-Beta-2
    Inhibitors. This report provides information on
    the therapeutic development based on the
    TGF-Beta-2 Inhibitors dealing with mechanism of
    action, comparative analysis at various stages
    covering Filed, Phase III, Phase II, Phase I, IND
    filed, Preclinical, Discovery and unknown stages,
    therapeutics assessment by monotherapy and
    combination products and molecule type drug
    information. The report also covers the companies
    information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant
    products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of TGF-Beta-2
    InhibitorsThe report provides pipeline products
    under drug profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the TGF-Beta-2 Inhibitors
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    typeThe report reviews key players involved in
    the therapeutics development for TGF-Beta-2
    Inhibitors and also provide company profilingThe
    report also gives the information of dormant and
    discontinued pipeline projects Pipeline products
    coverage based on various stages of development
    ranging from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete MOA intelligence and
    complete understanding over therapeutics
    development for TGF-Beta-2 Inhibitors
  • Identify the relationship between the drugs and
    use it for target finding, drug repurposing, and
    precision medicine.
  • Devise corrective measures for pipeline projects
    by understanding TGF-Beta-2 Inhibitors pipeline
    depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your
    drug development activities.
  • Optimize your portfolio and keep you in touch
    with the rapidly changing pharmaceutical markets,
    and make the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies
  • Modify the therapeutic portfolio by identifying
    discontinued projects and understanding the
    factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive
    Landscape for Evidence based DecisionsYou can
    order full Report with TOC and for Sample page
    visit _at_http//www.aarkstore.com/pharmaceuticals-h
    ealthcare/76036/tgf-beta-2-inhibitors-pipeline-ins
    ights-2014

7
Table of Content
  • TGF-Beta-2 Inhibitors OverviewTGF-Beta-2
    Inhibitors Disease AssociatedTGF-Beta-2
    Inhibitors Pipeline TherapeuticsTGF-Beta-2
    Inhibitors Therapeutics under Development by
    Companies TGF-Beta-2 Inhibitors Late Stage
    Products (Filed and Phase III)Comparative
    Analysis TGF-Beta-2 Inhibitors Mid Clinical
    Stage Products (Phase II)Comparative
    Analysis TGF-Beta-2 Inhibitors Early Clinical
    Stage Products (Phase I and IND
    Filed)Comparative Analysis TGF-Beta-2
    Inhibitors Discovery and Pre-Clinical Stage
    Products Comparative Analysis Drug Candidate
    Profiles

8
Table of Content
  • TGF-Beta-2 Inhibitors Therapeutics
    Assessment Assessment by Monotherapy
    Products Assessment by Combination
    Products Assessment by Route of
    Administration Assessment by Molecule
    Type TGF-Beta-2 Inhibitors Discontinued
    Products TGF-Beta-2 Inhibitors Dormant
    ProductsCompanies Involved in Therapeutics
    Development for TGF-Beta-2 Inhibitors Appendix M
    ethodology Contact Us Disclaimer

9
List of Tables
  • Number of Products under Development for
    TGF-Beta-2 Inhibitors by Therapy Area,
    2014Number of Products under Development for
    TGF-Beta-2 Inhibitors, 2014Number of Products
    under Development by Companies Comparative
    Analysis by Late Clinical Stage Products (Filed
    and Phase III), 2014Comparative Analysis Mid
    Clinical Stage Products (Phase II),
    2014Comparative Analysis Early Clinical Stage
    Products (Phase I and IND Filed),
    2014Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014Drug Candidates
    ProfilesTGF-Beta-2 Inhibitors Assessment by
    Monotherapy Products

10
List of Tables
  • TGF-Beta-2 Inhibitors Assessment by Combination
    Products TGF-Beta-2 Inhibitors Assessment by
    Route of Administration TGF-Beta-2 Inhibitors
    Assessment by Stage and Route of
    Administration TGF-Beta-2 Inhibitors Assessment
    by Molecule Type TGF-Beta-2 Inhibitors
    Assessment by Stage and Molecule Type TGF-Beta-2
    Inhibitors Therapeutics Discontinued
    Products TGF-Beta-2 Inhibitors Therapeutics
    Dormant ProductsProducts under Development by
    Companies, 2014

11
List of Figures
  • Number of Products under Development for
    TGF-Beta-2 Inhibitors by Therapy Area,
    2014Number of Products under Development for
    TGF-Beta-2 Inhibitors, 2014Late Clinical Stage
    Products (Filed and Phase III), 2014Mid Clinical
    Stage Products (Phase II), 2014Early Clinical
    Stage Products (Phase I and IND Filed),
    2014Discovery and Pre-Clinical Stage Products,
    2014TGF-Beta-2 Inhibitors Assessment by
    Monotherapy Products TGF-Beta-2 Inhibitors
    Assessment by Combination Products TGF-Beta-2
    Inhibitors Assessment by Route of
    Administration TGF-Beta-2 Inhibitors Assessment
    by Stage and Route of Administration TGF-Beta-2
    Inhibitors Assessment by Molecule
    Type TGF-Beta-2 Inhibitors Assessment by Stage
    and Molecule Type

12
Related Reports
  • 2015 Worldwide Medical Laboratories
    Industry-Industry Market Report
  • 2015 Worldwide Pharmaceutical Preparation Mfg.
    Industry-Industry Market Report
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • TGF-Beta-2 Inhibitors -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,TGF-Beta-2 Inhibitors-Pipeline
    Insights, 2014, report provides comprehensive
    insights about pipeline drugs across this
    mechanism of action (MOA).
    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com